Literature DB >> 16264828

Technology insight: Identification of biomarkers with tissue microarray technology.

Jena M Giltnane1, David L Rimm.   

Abstract

High-throughput technologies have been developed in the hope of increasing the pace of biomedical research, and accelerating the rate of translation from bench to bedside. Using such technology in target discovery has resulted in the need for systematic validation of the targets in an equally rapid manner. For example, gene expression microarrays have highlighted many potential targets in cancer, and tissue microarrays have emerged as a powerful tool to validate these targets by measuring tumor-specific protein expression and linking it to clinical outcome. Automated quantitative analysis of the tissue microarray 'spots' is beginning to take the technology a step further, removing observer bias, and providing standards for quality control and the potential for high-throughput analysis. The validation required for translation of tissue biomarkers from the research lab to the clinical lab will probably rely heavily on the combination of tissue microarray technology with automated quantitative analysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16264828     DOI: 10.1038/ncponc0046

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  49 in total

1.  DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.

Authors:  Xian Hua Gao; Zhi Qi Yu; Chang Zhang; Chen Guang Bai; Jian Ming Zheng; Chuan Gang Fu
Journal:  Int J Colorectal Dis       Date:  2011-11-12       Impact factor: 2.571

2.  Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray.

Authors:  Martin J Romeo; John Wunderlich; Lien Ngo; Steven A Rosenberg; Seth M Steinberg; David M Berman
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

3.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 4.  Factors to keep in mind when introducing virtual microscopy.

Authors:  Katharina Glatz-Krieger; Udo Spornitz; Alain Spatz; Michael J Mihatsch; Dieter Glatz
Journal:  Virchows Arch       Date:  2005-11-22       Impact factor: 4.064

Review 5.  [Virtual microscopy: first applications].

Authors:  K Glatz-Krieger; D Glatz; M J Mihatsch
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

6.  The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource.

Authors:  Claire S Zhu; Wen-Yi Huang; Paul F Pinsky; Christine D Berg; Mark Sherman; Kelly J Yu; Danielle M Carrick; Amanda Black; Robert Hoover; Petra Lenz; Craig Williams; Laura Hawkins; Matthew Chaloux; Susan Yurgalevitch; Sunitha Mathew; Amy Miller; Vanessa Olivo; Asia Khan; Shannon M Pretzel; Deborah Multerer; Patricia Beckmann; Karen G Broski; Neal D Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-15       Impact factor: 4.254

7.  Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Authors:  Daniel E Carvajal-Hausdorf; Kurt A Schalper; Lajos Pusztai; Amanda Psyrri; Konstantine T Kalogeras; Vasiliki Kotoula; George Fountzilas; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2015-05-19       Impact factor: 13.506

Review 8.  Recent developments in multiplexing techniques for immunohistochemistry.

Authors:  Angela R Dixon; Cédric Bathany; Michael Tsuei; Joshua White; Kate F Barald; Shuichi Takayama
Journal:  Expert Rev Mol Diagn       Date:  2015-08-06       Impact factor: 5.225

9.  Tissue microarrays: one size does not fit all.

Authors:  Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon
Journal:  Diagn Pathol       Date:  2010-07-07       Impact factor: 2.644

Review 10.  Tissue Microarray: A rapidly evolving diagnostic and research tool.

Authors:  Nazar M T Jawhar
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.